Eagle Pharmaceuticals Inc (EGRX) Shares Bought by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC lifted its holdings in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 28.5% during the third quarter, Holdings Channel reports. The institutional investor owned 28,322 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,286 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Eagle Pharmaceuticals were worth $1,964,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. lifted its stake in Eagle Pharmaceuticals by 21.6% in the third quarter. BlackRock Inc. now owns 1,741,712 shares of the specialty pharmaceutical company’s stock valued at $120,753,000 after purchasing an additional 309,622 shares during the last quarter. Matarin Capital Management LLC purchased a new position in Eagle Pharmaceuticals in the third quarter valued at approximately $8,137,000. Iridian Asset Management LLC CT raised its holdings in Eagle Pharmaceuticals by 8.7% during the 3rd quarter. Iridian Asset Management LLC CT now owns 935,398 shares of the specialty pharmaceutical company’s stock valued at $64,851,000 after acquiring an additional 74,487 shares during the period. Bank of America Corp DE raised its holdings in Eagle Pharmaceuticals by 183.6% during the 2nd quarter. Bank of America Corp DE now owns 70,833 shares of the specialty pharmaceutical company’s stock valued at $5,360,000 after acquiring an additional 45,857 shares during the period. Finally, Scout Investments Inc. bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at $3,121,000.

A number of brokerages have issued reports on EGRX. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine cut shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 21st. Cantor Fitzgerald cut shares of Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, November 1st. BidaskClub cut shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 7th. Finally, Royal Bank of Canada set a $64.00 price target on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $69.33.

In other news, CEO Scott Tarriff sold 30,085 shares of the company’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $41.54, for a total value of $1,249,730.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 28.20% of the company’s stock.

Eagle Pharmaceuticals stock opened at $41.41 on Wednesday. The firm has a market capitalization of $632.77 million, a PE ratio of 20.30 and a beta of 1.69. Eagle Pharmaceuticals Inc has a fifty-two week low of $36.03 and a fifty-two week high of $85.66. The company has a current ratio of 5.59, a quick ratio of 5.38 and a debt-to-equity ratio of 0.20.

WARNING: This story was originally posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://theenterpriseleader.com/2019/02/06/eagle-pharmaceuticals-inc-egrx-shares-bought-by-tiaa-cref-investment-management-llc.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Story: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply